The challenge of AML in older patients

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages

  Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AZACITIDINE; CD135 ANTIGEN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; NUCLEOPHOSMIN; SAPACITABINE; TIPIFARNIB; VOLASERTIB; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ANTIBIOTIC THERAPY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; ELDERLY CARE; FLT3 GENE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC SYSTEM; HUMAN; INDUCTION CHEMOTHERAPY; INTENSIVE CARE; LEUKEMIA REMISSION; LIMITED HEMATOPOIETIC RESERVE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NPM1 GENE; OVERALL SURVIVAL; PALLIATIVE THERAPY; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84897960662     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2013.038     Document Type: Review

References (34)

1. Goldstone A. H., Burnett A.K., Wheatley K., Smith A. G., Hutchinson R. M., and Clark R. E. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98 (5):1302-1311, 2001. http://dx.doi.org/10.1182/blood. V98.5.1302 PMid:11520775
2. Buchner T., Berdel W. E., Haferlach C., Haferlach T., Schnittger S., Muller-Tidow C., Braess J., Spiekermann K., Kienast J., Staib P., Gruneisen A., Kern W., Reichle A., Maschmeyer G., Aul C., Lengfelder E., Sauerland M. C., Heinecke A., Wormann B. and Hiddemann W. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27 (1):61-69, 2009. http://dx.doi.org/10.1200/JCO.2007.15.4245 PMid:19047294
3. Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., Cauchie C., Peetermans M., Solbu G., Suciu S. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7 (9):1268-1274, 1989. PMid:2475589
4. Juliusson G., Antunovic P., Derolf A., Lehmann S., Mollgard L., Stockelberg D., Tidefelt U., Wahlin A. and M. Hoglund. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113 (18):4179-4187, 2009. http://dx.doi.org/10.1182/blood-2008-07-172007 PMid:19008455
5. Burnett A. K., Milligan D., Goldstone A., Prentice A., McMullin M. F., Dennis M., Sellwood E., Pallis M., Russell N., Hills R. K., and Wheatley K. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 145 (3):318-332, 2009. http://dx.doi.org/10.1111/j.1365-2141.2009.07604.x PMid:19291085
6. Burnett A. K., Milligan D., Prentice A. G., Goldstone A. H., McMullin M. F., Hills R. K., and Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109 (6):1114-1124, 2007. http://dx.doi.org/10.1002/cncr.22496 PMid:17315155
7. Dohner H., Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenbert B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood;115:453-474. 2010. http://dx.doi.org/10.1182/blood-2009-07-235358 PMid:19880497
8. Wheatley K., Brookes C. L., Howman A. J., Goldstone A. H., Milligan D. W., Prentice A. G., Moorman A. V., and Burnett A. K. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br. J Haematol 145 (5):598-605, 2009. http://dx.doi.org/10.1111/j.1365-2141.2009.07663.x PMid:19344426
9. Buchner T., Urbanitz D., Hiddemann W., and et al. Intensive induction and consolidation with or without maintenance chemotherapy for acute myeloid leukaemia (AML): two multicenter studies of German AML Cooperative Group. Journal of Clinical Oncology 3:1583-1589, 1985. PMid:3906048
10. Berman E., Little C., Gee T., O'Reilly R., and Clarkson B. Reasons that patients with acute myelogenous leukaemia do not undergo allogeneic bone marrow transplantation. New England Journal of Medicine 326:156-160, 1992. http://dx.doi.org/10.1056/NEJM199201163260303 PMid:1727546
11. Burnett A. K., Russell N. H., Kell J., Kjeldsen L., Milligan D., Cahalin P., and Hills R.K. A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment of older patients with AML and high risk MDS: Results of the UK NCRI AML16 Trial. Blood 120, 2012 (abstr).
12. Kantarjian H. M., Erba H. P., Claxton D., Arellano M., Lyons R. M., Kovascovics T., Gabrilove J., Craig M., Douer D., Maris M., Petersdorf S., Shami P. J., Yeager A. M., Eckert S., Abichandani R., and Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28 (4):549-555, 2010. http://dx.doi.org/10.1200/JCO.2009.23.3130 PMid:20026805
13. Burnett A. K., Russell N. H., Kell J., Dennis M., Milligan D., Paolini S., Yin J., Culligan D., Johnston P., Murphy J., McMullin M. F., Hunter A., Das-Gupta E., Clark R., Carr R., and Hills R. K. European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy. J Clin Oncol 28;2389-2395, 2010. http://dx.doi.org/10.1200/JCO.2009.26.4242 PMid:20385984
14. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, and Milligan D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J. Clin. Oncol. 30 (32):3924-3931, 2012. http://dx.doi.org/10.1200/JCO.2012.42.2964 PMid:22851554
15. Castaigne S., Pautas C., Terre C., Raffoux E., Bordessoule D., Bastie J. N., Legrand O., Thomas X., Turlure P., Reman O., Revel T. de, Gastaud L., Gunzburg de N., Contentin N., Henry E., Marolleau J. P., Aljijakli A., Rousselot P., Fenaux P., Preudhomme C., Chevret S., and Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379 (9825):1508-1516, 2012. http://dx.doi.org/10.1016/S0140-6736(12)60485-1
16. Amadori S., Suciu S, Salih H, et al. The sequential combination of gemtuzumab ozogamicin and intensive chemotherapy does not benefit older patients with untreated AML: Results of the EORTCGIMEMA AML-17 randomised trial. Haematologica 97(1):521-522,2012.
17. Lowenberg B., Ossenkoppele G. J., van Putten W., Schouten H. C., Graux C., Ferrant A., Sonneveld P., Maertens J., Jongen-Lavrencic M., von Lilienfeld-Toal M., Biemond B. J., Vellenga E., Kooy M. V., Verdonck L. F., Beck J., Dohner H., Gratwohl A., Pabst T., and Verhoef G. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. New England Journal of Medicine 361 (13):1235-1248, 2009. http://dx.doi.org/10.1056/NEJMoa0901409 PMid:19776405
18. Lee J. H., Joo Y. D., Kim H., Bae S. H., Kim M. K., Zang D. Y., Lee J. L., Lee G. W., Lee J. H., Park J. H., Kim D. Y., Lee W. S., Ryoo H. M., Hyun M. S., Kim H. J., Min Y. J., Jang Y. E., and Lee K. H. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118 (14):3832-3841, 2011. http://dx.doi.org/10.1182/blood-2011-06-361410 PMid:21828126
19. Ohtake S., Miyawaki S., Fujita H., Kiyoi H., Shinagawa K., Usui N., Okumura H., Miyamura K., Nakaseko C., Miyazaki Y., Fujieda A., Nagai T., Yamane T., Taniwaki M., Takahashi M., Yagasaki F., Kimura Y., Asou N., Sakamaki H., Handa H., Honda S., Ohnishi K., Naoe T., and Ohno R. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117 (8):2358-2365, 2011. http://dx.doi.org/10.1182/blood-2010-03-273243 PMid:
20. Fernandez H. F., Sun Z., Yao X., Litzow M. R., Luger S. M., Paietta E. M., Racevskis J., Dewald G. W., Ketterling R. P., Bennett J. M., Rowe J. M., Lazarus H. M., and Tallman M. S. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J Med 361 (13):1249-1259, 2009. http://dx.doi.org/10.1056/NEJMoa0904544 PMid:19776406
21. Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK. Clofarabine Doubles the response Rate in Older Patients with Acute Myeloid Leukaemia but Does Not Improve Survival.
22. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, and Milligan D. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br. J. Haematol. 158 (4):519-522, 2012. http://dx.doi.org/10.1111/j.1365-2141.2012.09165.x PMid:22639959
23. Fenaux P., Mufti G. J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., Sanz G., List A. F., Gore S., Seymour J. F., Dombret H., Backstrom J., Zimmerman L., McKenzie D., Beach C. L., and Silverman L. R. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology 28 (4):562-569, 2010. http://dx.doi.org/10.1200/JCO.2009.23.8329 PMid:20026804
24. Kantarjian H. M., Thomas X. G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., Gau J. P., Chou W. C., Buckstein R., Cermak J., Kuo C. Y., Oriol A., Ravandi F., Faderl S., Delaunay J., Lysak D., Minden M., and Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 30 (21):2670-2677, 2012. http://dx.doi.org/10.1200/JCO.2011.38.9429 PMid:22689805
25. Hills R. K. and Burnett A. K. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood 118 (9):2389-2394, 2011. http://dx.doi.org/10.1182/blood-2011-02-337261 PMid:21734235
26. Roboz G.J., Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res. 35(4):522-5, 2011 http://dx.doi.org/10.1016/j.leukres.2010.09.010 PMid:20956016
27. Burnett, A. K., Hills, R. K., Hunter, A., Milligan, D., Kell, J., Wheatley, K., Yin, J., McMullin, M. F., Cahalin, P., Craig, J., Bowen, D., and Russell, N. The addition of arsenic trioxide to lowdose Ara-C in older patients with AML does not improve outcome. Leukemia 2011;25(7):1122-1127. http://dx.doi.org/10.1038/leu.2011.59 PMid:21475252
28. Harousseau J. L., Lancet J. E., Reiffers J., Lowenberg B., Thomas X., Huguet F., Fenaux P., Zhang S., Rackoff W., Porre De P., and Stone R. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109 (12):5151-5156, 2007. http://dx.doi.org/10.1182/blood-2006-09-046144 PMid:17351110
29. Lancet J. E., Gojo I., Gotlib J., Feldman E. J., Greer J., Liesveld J. L., Bruzek L. M., Morris L., Park Y., Adjei A. A., Kaufmann S. H., Garrett-Mayer E., Greenberg P. L., Wright J. J., and Karp J. E. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poorrisk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109 (4):1387-1394, 2007. http://dx.doi.org/10.1182/blood-2006-04-014357 PMid:17082323 PMCid:1794070
30. Burnett A. K., Hills R. K., Hunter A. E., Milligan D., Kell W. J., Wheatley K., Yin J., McMullin M. F., Dignum H., Bowen D., and Russell N. H. The addition of gemtuzumab ozogamicin to lowdose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27 (1):75-81, 2013. http://dx.doi.org/10.1038/leu.2012.229 PMid:22964882
31. Maertens J., Lübbert M., Fiedler W., Fouillard L., Haaland A., Brandwein J.M., Lepretre S., Reman O., Turlure P., Bug G., Müller-Tidow C., Krämer A., Voss F., Taube T., Fritsch H., Döhner H. Phase I/II study of volasertib (BI 6727), a Polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML). Blood 2012 (Abstr).
32. Kantarjian H. M., Garcia-Manero G., Luger S., Venugopal P., Maness L. J., Wetzler M., Stock W., Coutre S., Borthakur G., and Chiao J. A randomized phase 2 study of Sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse. Blood 114:438, 2009.(abstr).
33. Lancet J., Kantarjian H, Ravandi F, Bastien S, Alino K, Michelson G, Karp J. SNS 595 demonstrates clinical responses in a phase 1 study in acute leukemia Blood 16;110(11):442. 2009 (abstr.)
34. Dohner H. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115(3): p. 453-74. http://dx.doi.org/10.1182/blood-2009-07-235358 PMid:19880497